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Abstract 
Background: Skeletal dysplasia (SD) conditions are rare genetic diseases of the skeleton, encompassing a hetero-
geneous group of over 400 disorders, and represent approximately 5% of all congenital anomalies. Developments 
in genetic and treatment technologies are leading to unparalleled therapeutic advances; thus, it is more important 
than ever to molecularly confirm SD conditions. Data on ‘rates-of-molecular yields’ in SD conditions, through exome 
sequencing approaches, is limited. Figures of 39% and 52.5% have been reported in the USA (n = 54) and South Korea 
(n = 185) respectively.
Methods: We discuss a single-centre (in the UK) experience of whole-exome sequencing (WES) in a cohort of 15 
paediatric patients (aged 5 months to 12 years) with SD disorders previously molecularly unconfirmed. Our cohort 
included patients with known clinical diagnoses and undiagnosed skeletal syndromes. Extensive phenotyping and 
expert radiological review by a panel of international SD radiology experts, coupled with a complex bioinformatics 
pipeline, allowed for both gene-targeted and gene-agnostic approaches.
Results: Significant variants leading to a likely or confirmed diagnosis were identified in 53.3% (n = 8/15) of patients; 
46.7% (n = 7/15) having a definite molecular diagnosis and 6.7% (n = 1/15) having a likely molecular diagnosis. We 
discuss this in the context of a rare disease in general and specifically SD presentations. Of patients with known 
diagnoses pre-WES (n = 10), molecular confirmation occurred in 7/10 cases, as opposed to 1/5 where a diagnosis was 
unknown pre-test. Thus, diagnostic return is greatest where the diagnosis is known pre-test. For WGS (whole genome 
sequencing, the next iteration of WES), careful case selection (ideally of known diagnoses pre-test) will yield highest 
returns.
Conclusions: Our results highlight the cost-effective use of WES-targeted bioinformatic analysis as a diagnostic 
tool for SD, particularly patients with presumed SD, where detailed phenotyping is essential. Thorough co-ordinated 
clinical evaluation between clinical, radiological, and molecular teams is essential for improved yield and clinical care. 
WES (and WGS) yields will increase with time, allowing faster diagnoses, avoiding needless investigations, ensuring 
individualised patient care and patient reassurance. Further diagnoses will lead to increased information on natural 
history/mechanistic details, and likely increased therapies and clinical trials.
Keywords: Mendelian, Molecular genetic test, Monogenic, Next-generation sequencing, Skeletal dysplasia, Exome 
sequencing, Genome sequencing, Yield
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Background
Rare diseases by definition affect less than 1 in 2,000 
(in Europe) or 1 in 1,500 (in the USA). Approximately 
80% of the 7300 rare diseases have a known genetic 
cause, and whole-exome sequencing (WES) is com-
monly the final diagnostic step in such cases with diag-
nostic yields averaging around 31% (24–68%) [1–3].
The broad range in WES diagnostic yields (see 
Table  1) reflects varying cohorts and clinical indica-
tions for testing (i.e., diagnostic rates are higher in 
selected cohorts with conspicuous phenotypes). Yield 
is highly influenced by recruitment type (e.g., single 
proband versus trio), bioinformatic pipelines, study 
year, consanguinity, case complexity and degree of 
prior genetic evaluation. Yields tend to increase with 
study year (due to increasing novel genes, conditions, 
and technological advances) and in cohorts with a 
high degree of consanguinity [2]. Conversely yields are 
lower in cohorts with highly complex cases necessitat-
ing challenging interpretation, e.g. cases where two or 
three independent genetic diagnoses lead to an aggre-
gate phenotype. Yield is also markedly affected by the 
extent of prior genetic and metabolic evaluation; thus, 
WES usage earlier in the diagnostic assessment can 
lead to higher yields.
Skeletal dysplasia cohorts
The majority of rare diseases (50–75%) affect children 
[10]. In paediatric unsolved rare disease cohorts, the 
diagnostic yield from exome sequencing is around 40% 
[11]. An important subset of rare paediatric disease is 
skeletal dysplasia (SD). SD conditions are rare disor-
ders of the skeleton, encompassing a genetically het-
erogeneous group of over 400 distinct disorders. They 
represent approximately 5% of all congenital anomalies 
and are a significant contributory cause of children 
with severe short stature [12].
Yields in SD
Data on WES yields in SD cohorts are limited. In a large 
study of over 3000 rare diseases WES cases in a single US 
centre, Retterer et al., (2015) performed a subgroup anal-
ysis of 54 SD cases reporting a diagnostic yield of 39% 
(n = 54) [13]. Recruitment was predominantly trio based 
(> 75% were trios, 7% were duos) though the patients 
were at different points of their diagnostic evaluation. 
The average patient age was 11 − / + 13 years.
Bae et al. (2015) studied a large cohort of 185 patients 
with SD across multiple centres in South Korea, who had 
panel-based targeted exome sequencing (TES) (255 gene 
panel); 25 had a prior confirmed clinical and molecular 
diagnosis. Thus, TES was used to reconfirm molecu-
lar findings, 64 had an unknown clinical diagnosis, and 
96 patients had an assured clinical diagnosis [14]. A 
molecular diagnosis was ‘confirmed’ or ‘highly patho-
genic’ in 20% (n = 13/64) of patients with an unknown 
clinical diagnosis and 71% (n = 71/96) of patients with an 
assured clinical diagnosis. In this report, we explore the 
utility of WES in a cohort solely composed of SD presen-
tations and consider the diagnostic yield in sub-cohorts, 
i.e., those with an unknown diagnosis and those with an 
assured diagnosis (either single gene or heterogeneous). 
Although the number of patients in our study is small 
(n = 15), to the best of our knowledge, there are no previ-




All patients were study participants at the Guy’s and St 
Thomas’ Hospital clinical site. Our cohort spans the 
period; September 2014–2018. All patients within our 
cohort were paediatric (5 months to 12 years, mean age 
5.5 years).
15 patients with presumed SD conditions based on 
clinical and radiographic findings, were selected from 
the specialist SD multidisciplinary clinic. The majority 
Table 1 Diagnostic yield from NGS strategies in different rare disease cohorts in key publications
WES whole-exome sequencing; WGS whole-genome sequencing
Published year Journal Strategy Sequenced Diagnostic yield (%) Author
2013 NEJM WES 250 24.8 Yang et al. [4]
2014 AJHG WES 264 55.3 Beaulieu et al. [5]
2015 Nat Genet WGS* 156 21.2 Taylor et al. [6]
2017 JAMA Pediatr WES 44 52.3 Tan et al. [7]
2017 JAMA Pediatr WES 278 36.7 Meng et al. [8]
2017 JAMA Pediatr Critical trio WES 63 50.8 Meng et al. [8]
2018 NPJ Genome Med WGS* 42 42.9 Farnaes et al. [9]
2019 Sci Rep WGS* 10 62.5 Liu et al. [3]
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of participants were referred to the service from external 
facilities. Informed consent was obtained for all patients, 
and thereafter genomic DNA was extracted from the 
proband and where possible their parents. Many partici-
pants were at different stages of their evaluation.
Patients were recruited as trios (proband and both par-
ents) unless otherwise stated.
The 15 patients were divided into three categories 
based on the certainty of clinical diagnosis and the sta-
tus of the prospective genotype. Patients with an assured 
clinical diagnosis of an SD, where one or only a few geno-
types are known to be responsible (e.g., achondroplasia) 
were excluded as they are not appropriate for WES unless 
single gene testing was not readily available. Patients 
were then assigned one of three categories.
• Known condition–known gene (Category K–K)
• Unknown condition–unknown gene (Category 
U–U)
• Known condition/group of conditions–the possibil-
ity of multiple genes (Category K–U)
Exome sequencing and variant prioritisation
WES capture was performed using Agilent SureSelectXT 
Human All Exon V5 baited with clinically relevant genes 
followed by sequencing on an Illumina HiSeq 2500 
(though three of the later cases were sequenced on an 
Illumina NextSEQ 550). Raw sequence data were aligned 
using Novoalign, and variants called with Samtools. Cov-
erage of coding exons (+ / − 5 base pairs) was to a mini-
mum depth of × 20.
Variant analysis
Qiagen Ingenuity Variant Analysis was used to aid the 
assessment of variant pathogenicity after applying a vir-
tual panel of 222 SD genes (see Appendix 1) in combi-
nation with multidisciplinary clinical interpretation. 
Qiagen analysis uses (CGI 54 Genomes, SIFT, Exome 
Variant Server (EVS), Allele Frequency Community, JAS-
PAR, Ingenuity Knowledge Base, Vista Enhancer, BSIFT, 
TCGA, PolyPhen-2, 1000 Genome Frequency, Clinvar, 
COSMIC, ExAC, HGMD, PhyloP, DbSNP, TargetScan), 
and Alamut for splice site analysis (SpliceSiteFinder-like, 
MaxEntScan, NNSplice, GeneSplicer).
Sequencing data were analysed in three stages. In stage 
one, clinicians proposed primary genes or small gene-
panels for analysis through the WES platform that were 
likely to harbour the causative variant. This reduced the 
volume and cost of variants to analyse. If no significant 
variants were identified, then stage two involved apply-
ing and interpreting the 222 SD virtual gene-panel (see 
Appendix 1). If no appropriate variant was identified in 
stage two, then stage three involved a human pheno-
type ontology (HPO) driven whole-exome wide-search. 
HPO terms were derived by clinical geneticist expert 
review along with medical record evaluation and blinded 
radiographic review by three independent SD expert 
radiologists (CH/AO/AC). The phenotypic terms and dif-
ferential diagnosis provided were critical for analysis.
Molecular diagnosis using determined variants
Molecular diagnosis was made by correlating clinical and 
radiographic findings with candidate sequence variants 
through WES. The status of the molecular diagnosis was 
determined as either known or unknown.
Results
Our cohort of 15 patients comprised: five males and ten 
females, with ages ranging from 5  months to 12  years 
with an average age of 5.5 years old. Significant variants 
were identified in 53.3% (n = 8/15) of patients; 46.7% 
(n = 7/15) having a definite molecular diagnosis and 6.7% 
(n = 1/15) having a likely molecular diagnosis. One case 
(patient 15) after negative WES testing was concluded to 
have acquired SD aetiology. Thus, 60% (n = 9/15) cases 
had a confirmed or likely confirmed diagnosis (yield: 
60%).
Of unknown clinical diagnosis (n = 5/15), WES led to 
molecular confirmation (likely or highly likely) in 20% 
(n = 1/5).
Discussion
SD diagnoses are challenging for several reasons. Firstly, 
similar phenotypes are heterogeneous; one gene can 
cause several conditions. Secondly, the aetiology of mul-
tiple SD conditions is unknown or their phenotype not 
well established. Thirdly, the experience of SD conditions 
by individual clinicians is limited, and lastly, the charac-
teristic features of many SD conditions only manifest at 
certain periods. For example, stippled epiphyses (char-
acteristic of chondrodysplasia punctata) are only pre-
sent in the neonatal or infantile period; thus, diagnoses 
are difficult without timely investigation. Similarly, many 
characteristic features disappear after skeletal maturity or 
only present when young. Multidisciplinary approaches, 
involving geneticists, radiologists, orthopaedic, growth 
specialists and therapists (occupational, physiotherapy, 
psychological), are often necessary for diagnosis and 
management of SD conditions.
Using a single-gene testing strategy is often unhelpful 
for the reasons stated, and increasingly WES or WGS 
options are deployed. In some countries specific panels 
are used, in place of or prior to WES/WGS, due to lower 
costs, accessibility and relatively large numbers of genes 
specific to the phenotype. Infact many WES or WGS 
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approaches begin with panel-based analysis before more 
agnostic or wider analysis. Little is reported regarding the 
diagnostic yield of WES in SD conditions, as often such 
cases are pooled in general rare disease cohorts. Where 
rates and analysis have been reported, little is discussed 
around the prior categorisation of cases (e.g., whether the 
diagnosis was known).
Despite these challenges, yields for SD conditions are 
relatively high compared to other rare disease catego-
ries. In fact, for fetal anomalies, the highest yields (~ 80%) 
were obtained in the SD category in the UK fetal exome 
PAGE (prenatal assessment of genomes and exomes) 
study [15]. However, the yield is less spectacular postna-
tally. Retterer et al. report a yield of 39% in SD patients 
(n = 54) using WES in a combined paediatric and adult 
cohort [13]. Bae et  al., reported a likely or confirmed 
molecular diagnosis in 52.5% (n = 84/160) through TES, 
though the patient ages are not reported [14].
To diagnose SD conditions, radiographic imaging in 
early childhood is key; thus, our cohort of only paedi-
atric patients consisted of suitably appropriate clinical-
radiographic data for further genetic investigation. None 
of the patients had molecular confirmation of their con-
dition before WES testing. Upon WES testing, a three-
stage approach to variant analysis (as outlined in the 
methods) was undertaken. This allowed molecular sci-
entists to focus their search, identifying pathogenic vari-
ants efficiently and saved time spent analysing less likely 
variants.
Significant variants leading to a likely or confirmed 
diagnosis were identified in 53.3% (n = 8/15) of patients; 
46.7% (n = 7/15) having a definite molecular diagnosis 
and 6.7% (n = 1/15) having a likely molecular diagnosis. 
In comparison, Bae et al. reported a likely or confirmed 
molecular diagnosis in 52.5% (n = 84/160) of similar 
patients (excluding those patients who had molecular 
confirmation prior to WES testing) [14]. This means that 
our yield was comparable to Bae et al., and was margin-
ally higher. If we include patient 15 as a confirmed diag-
nosis, who after negative WES testing was concluded to 
have an acquired SD aetiology, then our yield reached 
60% (n = 9/15).
The possible reasons for a slightly higher yield as com-
pared to Bae et  al. includes increased gene discovery 
linked to SD conditions since Bae et  al. was published 
(2016), improved bioinformatic pipelines, technological 
advances in next-generation sequencing machinery (e.g. 
improved coverage and read depth) and triple radiologi-
cal review within our analysis (all three reviewers being 
expert contributors to the International Skeletal Dys-
plasia Society) [14]. We note that radiological input was 
key with patients 2 and 4. For patient 2, the radiology 
review led to a change in the pre-test working diagnosis 
from spondyloepiphyseal dysplasia congenita (SEDC) to 
campomelic dysplasia (CD), enabling a better genotype–
phenotype match, thus securing the diagnosis. Likewise, 
the radiological diagnosis with patient 4 identified the 
correct spectrum of disorders so that when a COL11A2 
(collagen type XI alpha-2 chain) variant was found, the 
appropriate final diagnosis was more easily identified.
Of patients with a known diagnosis pre-WES (n = 10), 
WES led to a confirmed molecular diagnosis in 7/10 
cases (rising to 8/10 if we include patient 8 as another 
confirmed diagnosis, though of an acquired cause). This 
highlights the significant return when there is a known 
diagnosis pre-test.
Of patients with unknown clinical diagnoses (n = 5/15), 
WES led to molecular confirmation (likely or highly 
likely) in 20% (n = 1/5) of cases which is the same detec-
tion rate as Bae et al. [14] This was expected considering 
low pre-test diagnostic SD hypotheses.
WES yields for non-SD conditions (25–51%, see 
Table  1) are generally lower than for SD disorders (this 
study; up to 60% and Bae et al. 52.5%) [14]. This is likely 
due to the rich combination of radiology and clinical fea-
tures, and synergism between multiple experts, enhanc-
ing phenotypic-driven bioinformatics analysis.
We further discuss selected patients to extrapolate 
key learning points and have grouped the patients into 
themes.
Theme 1: known clinical diagnosis with clear single‑gene 
cause, but testing unavailable
Patient 1 had a clinical diagnosis of spondyloepiphyseal 
dysplasia tarda (SEDT; OMIM #313,400). SEDT is caused 
by heterozygous TRAPPC2 (tracking protein particle 
complex subunit 2) variants. Several males across mul-
tiple generations had a similar diagnosis but no known 
genetic testing. At the time of diagnosis in patient 1 
(2014), TRAPPC2 testing was not readily available in 
the UK (except on a research basis) [16]. Thus, WES 
was performed, with primary analysis directed towards 
TRAPPC2. A pathogenic TRAPPC2 variant was iden-
tified (see Table  2). With many laboratories moving to 
WES and WGS, the availability of many single-gene tests 
is decreasing; thus, WES approaches with targeted analy-
sis are becoming ubiquitous. It is therefore crucial that 
clinicians make a pre-test diagnosis to enable targeted 
analysis and prevent the generation of unwanted and 
unrelated variants.
Theme 2: known clinical diagnosis (heterogeneous 
condition), multiple potential genetic causes
Patient 4 had macrocephaly, a flat facial profile, nasal 
bridge depression, small nose, micrognathia, a small 





































Table 2 Summary of patients with categorisation, features, and pre- and post-testing diagnosis
Patient Sex Age Category Clinical presentation Variants Inheritance Studies Revised diagnosis
1 M 11y K–K Spondyloepiphyseal dysplasia tarda
X- Linked
Hemizygous deletion of TRAPPC2 
exon 6
Maternally inherited Spondyloepiphyseal dysplasia tarda 
(X-Linked)†
2 F 10y K–K Spondyloepiphyseal dysplasia con-
genita
Heterozygous SOX9 c.508C > T, 
p.(Pro170Ser) variant detected
De-novo variant not present in parents Surviving campomelic dysplasia (CD)†
3 F 5 m K–K Syndromal proportional extreme short 
stature, Chiari malformation type I, 
growth hormone deficiency, hydro-
cephalus. Suspected Laron syndrome
No pathogenic variants were detected Not applicable SD of unknown aetiology‡
4 F 0-1y K–U Mild fibrochondrogenesis type 2. Post 




c.2542C > T p.(Gln848Ter) variant 
detected (mat)
Heterozygous COL11A2 c.3151-2delA 
variant detected (pat))




5 F 6y K–U Multiple epiphyseal dysplasia with non-
specific myopathy, or metaphyseal 
dysplasia
Heterozygous MATN3 c.400G > A 
p.(Glu134Lys)
Variant not present in mother. Father 
not tested
Multiple epiphyseal dysplasia†
6 F 8y K–U Intrauterine growth restriction (IUGR), 
failure to thrive, developmental delay, 
microcephaly, dysmorphisms, short 
stature. Type of microcephalic osteo-
dysplastic primordial dwarfism
Heterozygous PCNT c.5812C > T 
p.(Gln1928Ter) variant detected
Heterozygous PCNT c.9273 + 1G > C 
variant detected
AR—one variant inherited from each 
parent—trans
Microcephalic osteodysplastic primordial 
dwarfism type II†
7 M 3y K–U Metaphyseal chondromatosis with 
D2-hydroxyglutaric aciduria
Heterozygous IDH1 c.395G > A 
p.(Arg132His) variant detected
De novo—variant not present in 
parents
Metaphyseal chondromatosis with 
D2-hydroxyglutaric aciduria†
8 F 2y K–U Chondrodysplasia punctata. Query 
genetic or teratogen
No pathogenic variants were detected Not applicable Possible acquired aetiology§
9 F 11y K–U AR osteopetrosis (infantile onset) Heterozygous
CLCN7 c.1468delC p.(Leu490fs) variant 
detected (pat)
Heterozygous
CLCN7 c.1853C > A p.(Ala618Asp) vari-
ant detected (mat), VUS
AR—one variant inherited from each 
parent—trans
AR osteopetrosis type 4 (infantile onset) 
†
10 M 12y K–U Acromesomelic dysplasia, Maroteaux 
type, or spondylarperipheral
No pathogenic variants were detected Not applicable SD of unknown aetiology‡
11 F 3y K–U Odontochondrodysplasia No pathogenic variants were detected Not applicable Odontochondrodysplasia¶
12 M 1y U–U Disproportionate short stature, 
conductive hearing loss, percutane-
ous endoscopic gastrostomy fed, 
dysmorphisms




































† Confirmed molecular diagnosis
‡ Unknown diagnosis
§ Possible acquired diagnosis
¶ Confirmed clinical diagnosis but nil molecular findings
^Possible molecular diagnosis
K–K known condition–known condition; K–U known condition–unknown condition; U–U unknown condition–unknown condition; SD skeletal dysplasia; AR autosomal recessive; TRAPPC2 tracking protein particle 
complex, subunit 2; SOX6 sex determining region Y-box 6); COL11A2 collagen type XI alpha-2 chain; MATN3 matrilin-3; PCNT pericentrin; IDH1 isocitrate dehydrogenase 1; CLCN7 chloride voltage-gated channel 7; VUS 
variant of unknown significance; EXT2 exostosin glycosyltransferase 2; EDS Ehlers–Danlos syndrome
Table 2 (continued)
Patient Sex Age Category Clinical presentation Variants Inheritance Studies Revised diagnosis
13 F 2y U–U SD; congenital heart disease, 
hemimegaloencephaly, bilateral iris 
colobomata, hearing loss
Heterozygous EXT2 c.237G > A 
p.(Trp79Ter) variant detected (mat)
Heterozygous EXT2 c.1404 + 2 T > C 
variant detected (pat)
AR—one variant inherited from each 
parent—trans
Autosomal recessive exostosin glycosyl-
transferase 2 syndrome^
14 M 7y U–U Query EDS (classic type/collagen-
opathy), or Mandibular acrodysplasia 
type A
No pathogenic variants were detected Not applicable SD of unknown aetiology‡
15 F 6y U–U Unknown SD, rule out bone marrow 
transplant-related short stature
No pathogenic variants were detected Not applicable Bone marrow transplant-related short 
stature§
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metaphyses. The original diagnosis was ‘mild’ fibrochon-
drogenesis type 2 (FBCG2; OMIM #614524), which is 
caused by COL11A2 variants and can be lethal. The dif-
ferential included fibrochondrogenesis type 1 (OMIM 
#228520) caused by COL11A1 as well as Stickler syn-
drome (OMIM #108300) hence multiple genes could 
be potentially causative; thus, WES was an appropriate 
strategy. The radiological review noted vertebral coronal 
and sagittal clefts and with increasing age (see Fig.  1); 
enlarged epiphyses and clinically hearing loss became 
manifest. This led to an alteration of the diagnosis to 
otospondylomegaepiphyseal dysplasia (OSMED; OMIM 
#215150), an allelic disorder to FBCG2. WES confirmed 
compound heterozygous COL11A2 variants which cause 
a spectrum of disorders from mild deafness to OSMED to 
potentially lethal FBCG2. This case illustrated radiologi-
cal (e.g. mega-epiphyses) and clinical clues (hearing loss) 
that may only become apparent with time. It also high-
lights the need for clinicians to be careful of using ‘old’ 
diagnostics labels as milder forms of previously ‘lethal’ 
conditions or what we considered ‘extremely’ severe phe-
notypes are emerging. In such instances, umbrella terms 
like COL11A2-spectrum disorder as a pre-molecular 
diagnosis may be more apt rather than FBCG2.
Patient 5, a six-year-old male of normal stature who 
presented with leg pain, genu valgum, pes planus, mus-
cle weakness and decreased hip mobility. His clinical 
picture and radiology suggested possible multiple epi-
physeal dysplasia (MED; OMIM #132400) with non-
specific myopathy. Creatinine kinase was normal, and 
electromyography suggested myopathic disorder, muscle 
biopsy showed mild type 2 fibre atrophy and array Com-
parative Genomic Hybridisation (aCGH) was normal. 
MED is characterised by multiple long and or short bone 
epiphyseal abnormalities and has autosomal dominant 
(ADMED; OMIM #132400) and autosomal recessive 
(ARMED; OMIM #226900) forms [17, 18]. ADMED can 
be due to; COMP (cartilage oligomeric matrix protein), 
COL9A1-COL9A3 (collagen type IX alpha 1–3 chain) 
or MATN3 (matrilin 3) and presents in childhood with 
joint pain, exercise-induced fatigue, restricted mobil-
ity, short stature, and early-onset osteoarthritis [18]. 
ARMED is caused by SLC26A2 (solute carrier family 26, 
member A2) formerly known as DTDST (diastrophic 
dysplasia sulfate transporter) and presents with joint pain 
and often mild short stature. SLC6A2 is responsible for 
three allelic skeletal dysplasias; (in increasing severity) 
diastrophic dysplasia, atelosteogenesis 2 and achondro-
genesis type 1B [17]. Further key ARMED differentials 
include; mild mucolipidosis III (OMIM #252605) and 
mucopolysaccharidosis VI (OMIM #253000), both reces-
sive storage disorders discriminated from ARMED by 
coarse dysmorphic facies, intellectual disability, visceral 
involvement, marked spondylar disease and shorter stat-
ure [1].
Radiology showed delayed epiphyseal (long-bone) ossi-
fication and small and irregular epiphyses (especially in 
the knees and hips) (see Fig. 2). Due to MED heteroge-
neity, WES was an appropriate strategy for molecular 
diagnosis and identified a pathogenic MATN3 variant 
confirming MED Type 5 (OMIM #607078).
Patient 7 presented aged 3 years with an undefined SD, 
multiple falls, complex congenital heart disease (CCHD), 
relative macrocephaly and mild developmental delay. 
Skeletal survey at 10 months highlighted irregular meta-
physes. He had leg-length discrepancy, right leg bowing, 
mild joint hypermobility and hypotonia. Further radiol-
ogy (Fig. 3a, b) revealed worsening metaphyseal dyspla-
sia (expansion, cup-shaped irregularity) with radiolucent 
non-ossified cartilage affecting major joints. At 6.5 years, 
hand radiology showed severe widespread bilateral multi-
ple enchondromas (see Fig. 3c), that were also present in 
the lower limbs (see Fig. 3a). The diagnosis was felt to be 
an enchondromatosis-like condition and upon radiologi-
cal review; metaphyseal chondromatosis with D-2-hy-
droxyglutaric aciduria (MC-D2HGA; OMIM #614875) 
was suspected. Though MC-D2HGA was highly sus-
pected, other genetic disorders with very similar pheno-
types remained thus WES was an appropriate strategy.
Enchondromatosis (EC) is a rare heterogeneous con-
dition with multiple enchondromas (benign hyaline 
cartilage forming tumours in the metaphysis) [19]. The 
commonest two subtypes are Ollier disease (OMIM 
#166000) and then Maffucci syndrome (OMIM #614569) 
[19]. MC-D2HGA is another rarer subtype with only 11 
reported cases (four of which are due to somatic mosai-
cism of IDH1 (isocitrate dehydrogenase 1), the remainder 
lacking molecular confirmation) (Fig. 4) [20].
WES testing identified a de novo heterozygous IDH1 
c.395G > A p.(Arg132His) germline variant (approxi-
mately indicative allele frequency of 50/50, wild type: a 
variant on Sanger). Urinary organic acid testing showed 
marked isolated increase in 2-hydroxyglutarate, con-
firming MC-D2HGA (this result came after WES was 
initiated but prior to the WEST results). MC-D2HGA 
is associated with macrocephaly, developmental delay, 
hypotonia, significant metaphyseal dysplasia, enchon-
dromatosis, dysmorphia and CCHD. This is the first 
reported MC-D2HGA case caused by germline IDH1 
changes (with read depth over the IDH1 variant position 
of >  × 250 depth) though the author is aware of one unre-
ported MC-D2HGA case caused by germline changes 
(Zankl A. [Presentation] 6th Nordic Workshop on Skel-
etal Dysplasia, Karolinska Institute, Sweden. 5th March 
2020.) Had a WES approach not been used, it would have 
been difficult to reach this diagnosis.
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Patient 9 presented with osteopetrosis, a heteroge-
neous condition, classically divided into; fatal infan-
tile malignant form (OMIM #259700/611490/259720), 
Albers-Schonberg disease (OMIM #166600/259700) 
and a milder adult form. She presented with facial 
nerve palsy, and subsequent radiography noted Rickett-
sial-like bony ends (see Fig. 5). Foraminal impingement 
led to hearing loss and visual problems and a working 
diagnosis of infantile-onset osteopetrosis was estab-
lished, suitable for WES. The proband had compound 
heterozygous variants in CLCN7 (chloride voltage-
gated channel 7); a pathogenic variant inherited from 
her unaffected father and a VUS (variant of unknown 
significance) from her unaffected mother, though 
her maternal grandmother was affected (late-onset 
osteopetrosis) and had the same VUS. It later transpired 
that the mother actually had mild radiographic and 
clinical features demonstrating segregation and striking 
intrafamilial variable expression of osteopetrosis type 4 
(OMIM #611490). If PP4 (protein phosphate-4) or PP1 
(protein phosphate-1) panels were applied, the VUS 
would be upgraded to likely pathogenic. The paternal 
variant alone did not manifestly cause disease in the 
father but was felt to negatively modify the severity of 
the condition in the presence of the maternal variant.
Theme 3: known diagnosis, no known gene
In 2015, Patient 11, aged 3,presented with severe short 
stature, delayed motor milestones, a high-pitched voice, 
dysmorphism,  ligamentous laxity,  instability of the cer-
vical spine, severe scoliosis (see Fig. 6a, b), discoloured/
weak dentition (see Fig. 6c), and no fractures. The work-
ing diagnosis  after radiological review was  a rare form 
of  ‘spondylometaphyseal dysplasia with dentinogenesis 
imperfecta, odontochondrodysplasia (OMIM #184260). 
At the time, this condition had no known gene cause. 
Thus, an agnostic approach via WES was appropriate for 
new gene discovery. No pathogenic variants were found. 
Some years later, a causative gene was discovered for the 
condition, TRIP11(thyroid receptor-interacting protein 
11) though despite re-analysis, a molecular cause was not 
confirmed in patient 11. Other genetic causes of odonto-
chondrodysplasia are still sought.
Theme 4: unknown SD diagnosis
Patient 13 presented with SD (short stature, macroceph-
aly, and scoliosis) with non-skeletal syndromal features 
(congenital heart disease and hearing loss). CHD7 (chro-
modomain helicase DNA binding protein 7) gene testing 
Fig. 1 (patient 4, OSMED). a and b Age day 3; sagittal spinal clefts, coronal spinal clefts. c and d age 6 years; mega-epiphyses of the femoral head, 
wide metaphyses, C-shaped left convexity of the spine, marked anterior wedging of T11, T12 and L1
Fig. 2 (patient 5, MED). a Age 7 years; bilateral femoral head 
epiphyseal dysplasia, medial aspects fragmented. b Age 11 years; 
genu valgum and underdeveloped distal medial femoral epiphyses
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for CHARGE syndrome (OMIM #214800) was negative. 
WES identified two likely pathogenic variants in EXT2 
(exostosin glycosyltransferase 2) found in trans with clin-
ical findings overlapping for AREXT2 syndrome (autoso-
mal recessive exostosis-2 gene syndrome). AREXT2 is an 
ultra-rare recessive disorder with an unclear and expand-
ing phenotype as only four families have been reported 
[21]. First described in 2015, it was termed Seizures, 
Scoliosis and Macrocephaly syndrome (SSM; OMIM 
#616682). Later authors suggested the ‘AREXT2’ label to 
recognise the lack of uniformity of scoliosis or seizures. 
It is unclear whether patient 13 has AREXT2 thus, func-
tional work is required. In this unknown syndromal case, 
WES has ruled out many potential diagnoses and the 
Fig. 3 (patient 7, metaphyseal chondrodysplasia—D2-HGA type). a Age 7 years; left leg is longer than right, marked left-sided genu valgum. 
Multiple expansile lucent metaphyseal lesions involving bilateral femora and tibia. b Age 2.5 years; expansion and irregularities of vertebral bodies. c 
Age 7 years; extensive enchondromatosis of both hands and wrists with associated soft tissue swelling
Fig. 4 (patient 8, acquired SD). Aged 2 months; a sacral stippling, small, round/ovoid vertebral bodies with coronal clefts in the thoracic spine. b 
Sacral stippling. c short first metacarpals. d stippled epiphyses distal to the tibia and delayed ossification of the tarsal bones
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WES-based agnostic approach allowed for further inves-
tigation of an emerging ultra-rare condition.
Theme 5: WES to exclude a genetic diagnosis and support 
an acquired cause
Chondrodysplasia punctata (CDP) is a rare SD charac-
terised by punctiform calcification of cartilage and is 
acquired or genetic in origin [22]. Genetic forms (OMIM 
#302950/118650) are heterogeneous. Acquired forms can 
be due to maternal malabsorption of vitamin K, maternal 
warfarin or some anticonvulsant [23]. Patient 8, a 2-year-
old female, presented with faltering growth and antenatal 
exposure to lamotrigine and topiramate. Antenatal scans 
demonstrated short long-bones. Post-natal radiology 
(see Fig. 4a–d) showed sacral stippling with delayed tar-
sal ossification, consistent with CDP [24]. Since several 
genes cause CDP, WES is an appropriate strategy to rea-
sonably exclude underlying genetic causes. Thus, nega-
tive WES increases antenatal anticonvulsant exposure 
as the likely cause. Although there is no reported asso-
ciation of lamotrigine and topiramate, causing stippling, 
other Hydantoin anticonvulsants (e.g. phenytoin) have 
been reported to do so [23]. This case highlights the need 
for early radiography, as stippling is often only seen in the 
first year of life and rarely after age three [25].
Patient 15 was born with normal birth and growth 
parameters until age 11  months when an unexplained 
prolonged fever led to a diagnosis of haemophagocytic 
Fig. 5 (patient 9, infantile osteopetrosis). a and b Aged 1 year; thickened cortex skull, bone-in-bone appearance of vertebrae, anterior concavity. c 
Age 8 years; sclerotic pelvic bones/femora
Fig. 6 (patient 11, odontochondrodysplasia). a, b Aged 5.5 years; severe s-shaped scoliosis, marked platyspondyly, segmentation abnormality at 
T4/5, spondylolisthesis, slender ribs posteriorely with mild anterior rib flaring, proximal femoral metaphyseal dysplasia. c 3 years dentine dysplasia
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lymphohistiocytosis (OMIM #603553). Biallelic PRF1 
(Perforin-1) pathogenic variants (compound heterozy-
gote) were confirmed. At 18 months, matched unrelated 
cord blood HSCT (homologous stem cell transplanta-
tion) was performed. Subsequent progressive growth 
failure developed, associated with radiographic spondy-
loepimetaphyseal chondrodysplasia (progressive changes 
as shown in Fig.  7a–f, note radiographs prior to HSCT 
were not take as skeletal dysplasia was not suspected 
then), functional asplenia and sensorineural hearing loss. 
Development of skeletal changes throughout childhood 
including fixed flexion hip deformity, marked pes planus, 
marked genu valgum and pectus carinatum. Extensive 
endocrine investigations returned no cause. WES (and 
subsequent WGS) was negative for a skeletal cause. An 
international group of SD experts noted the similarity of 
this case and several others, concluding a potentially new 
disorder manifesting with growth failure and a chondro-
dysplasia phenocopy post early HSCT for non-oncologi-
cal disorders [26]. This case highlights the utility of WES 
to reduce the likelihood of a genetic cause significantly 
and increase the confidence of an acquired cause [26].
Further discussion
As many previous studies have discussed, a broad 
approach to genetic testing through WES or WGS allows 
for the identification of conditions that may not have 
been suspected clinically and thus the expansion of pre-
viously known phenotypes.
In our cohort of 15 patients, the use of WES has led to 
three novel findings. Firstly, Patient 7 is the first reported 
case of MC-D2HGA due to a germline variant. Secondly, 
patient 13, is potentially the fifth reported family with 
AREXT2 syndrome providing further expansion of the 
phenotype. Lastly, patient 15, is one of seven patients 
who have collectively provided evidence for a new dis-
ease, ‘chondrodysplasia phenocopy post early HSCT for 
non-oncological disorders’ and has been submitted for 
publication [26].
Although WES remains the current ‘go-to’ diagnostic 
test in many rare disease scenarios, we increasingly see 
a shift to WGS, especially for the acutely ill child. Even 
then, a large body of undiagnosed patients remain. When 
WES returns negative or inconclusive results, for many, 
the diagnostic odyssey is abandoned or halted. Yet it 
is clear that re-analysis of WES data can often result in 
diagnosis in 10–15% of these cases [2].
Additional testing such as long read sequencing (LRS), 
copy number variants (CNV) in non-coding regions, 
non-coding variants (NCV), repeat expansion (RE), 
methylation testing (MT) and other structural changes 
will need to be explored to increase diagnostic yield. 
Burdick et al. explored the proportion of diagnoses from 
additional testing in 54 patients with clinical diagnoses, 
enrolled in their Undiagnosed Disease Network [2]. Of 
the 54 participants, the molecular diagnosis was obtained 
in 36 (67%) through WES, and in 15 (28%) through addi-
tional testing. Of these, 7/15 (47%) had an NCV, 6/15 
(40%) a CNV, and 2/15 (13%) had a RE or a DNA meth-
ylation disorder. A yield figure could not be given since 
there were many other patients within the programme, 
who were at different stages of assessment. Nevertheless, 
the report highlights the benefit of testing beyond WES 
and the approaches that can be considered.
This combined with the advance of radiomics (the sys-
tematic use of artificial intelligence to provide diagnostic 
processing and analysis of ever sophisticated imaging 
data) will usher in an increased yield. The careful com-
bination of the physician (endocrinologist, orthopaedic 
surgeon), radiologist and geneticist working together will 
be crucial.
The difficulty with large scale sequencings, such as 
WES or WGS is the generation of large numbers of 
variants of unknown significance (VUS), especially as 
genetic testing, is mainstreamed. Likewise, bioinformatic 
Fig. 7 (patient 15, post HSCT related SD). a–c Aged 5 years; broad ribs, platyspondyly, proximal femoral epiphyseal dysplasia/metaphyseal 
irregularity. d–f Age 8 years; progressive changes; broadening of ribs, worsening vertebral end-plate irregularities, diffuse platyspondyly, increased 
density of carpal bones (excluding the hamate and capitate),increase phalangeal epiphyseal density, dense distal ulnar with v-shaped chondroid 
type calcification extending distally
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pipelines can present de-novo variants with strong com-
putational evidence suggestive of particular conditions, 
that are not easy to dismiss. The present challenge is, 
therefore, that of ‘variant interpretation’. Further familial 
segregation is not always possible.
Traditionally, one way to assess a VUS is to perform 
functional studies (e.g. fresh blood samples to undertake 
RNA studies to see if the DNA change has a functional 
impact on RNA production and therefore on the given 
protein). This method is challenging as it requires fresh 
blood samples (as RNA degrades quickly), a difficulty, 
especially in the paediatric population and blood samples 
are not always the appropriate sample to test a particu-
lar variant as the gene of interest may not particularly be 
expressed.
Additionally, RNA studies are not always possible in the 
NHS diagnostic lab, and clinicians often had to partner 
with university academics or other institutions for func-
tional work (often by providing fresh blood samples, or 
skin samples or saliva). The problems with this are mani-
fold; time-intensive and dependent on knowing suitable 
partners. Furthermore, obtaining the required sample 
can be difficult; we have already discussed the difficulty 
with blood samples. Skin samples require a skin biopsy 
which is a relatively invasive procedure. Saliva samples 
are often difficult to work with, of poor quality/limited in 
what can be assessed. Lastly, with more and more func-
tional study requests to academics, the boundaries of 
responsibility for what are essentially research analyses 
are blurred, thus increasing reluctance from academia to 
perform such work (culpability issue). Suitable new ‘quick 
and easy’ tests need developing for variant analysis, and 
hair pluck analysis may be one such avenue in the SD 
domain, due to beneficial expression profiles of SD genes.
Conclusion
Although the genetic causes of > 450 forms of skeletal 
disorders have been rapidly uncovered, distinct SD con-
ditions of unknown genetic aetiology remain [27]. The 
best strategy for identifying these may be the unbiased 
approach of WES or WGS, especially in children and 
patients with severe or multi-systemic diseases. It can 
be particularly beneficial to detect de novo pathogenic 
variants using a trio design. In sporadic cases, analysis of 
trios may reveal de-novo pathogenic variants. In famil-
ial cases, a combination of WES and either WGS or SNP 
typing could yield linkage information for prioritisation 
of rare variants [28]. If no variants are identified through 
WES, then further testing is needed, though the cost-
effectiveness of such studies needs determination [2].
Our results highlight the cost-effective use of WES-
targeted bioinformatic analysis as a diagnostic tool for 
SD, particularly for patients with presumed SD, where 
detailed phenotyping is essential. The thorough clinical 
evaluative approach and planning between clinical, radi-
ological, and molecular teams is essential for improved 
service provision.
As we move towards WGS trio sequencing, experi-
ence and this study shows that careful categorisation of 
patients of those with known pre-test diagnosis will yield 
a higher return of molecular confirmation (8/10 in this 
study) as opposed to unknown diagnosis pre-test (1/5 in 
this study) thus highlighting the importance of carefully 
selecting the most suitable cases for highest WGS yield. 
With the evolution of this pilot study, the SD panel was 
extended to 498 genes and anecdotally several more pre-
test unknown SD cases were molecularly resolved, thus it 
is felt WES/WGS will play a more significant role in cases 
with no prior test diagnosis.
The clinical yield of WES will increase over time, allow-
ing providers to arrive at a diagnosis efficiently. This 
information will help avoid needless diagnostic proce-
dures/costly additional tests and individualised patient 
care, allowing for informative clinical decisions and reas-
surance to patients and families [13]. More diagnoses 
will, in turn, lead to more information on natural history, 
improved mechanistic details, and hopefully increased 
therapies and clinical trials.
Appendix 1: The skeletal dysplasia gene panel 
v1 (222 genes, ‘Pan 272’) in accordance with UK 
Genetic Testing Network
ACAN, ACP5, ACVR1, ADAMTSL2, AGPS, ALPL, 
ALX1, ALX3, ALX4, ANKH, ANO5, ANTXR2, ARH-
GAP31, ARSE, ATP6V0A2, B3GALT6, B4GALT7, 
BMP1, BMP2, BMPR1B, CA2, CANT1, CASR, 
CC2D2A, CCDC8, CDC6, CDH3, CDKN1C, CDT1, 
CEP290, CHST14, CHST3, CHSY1, CLCN5, CLCN7, 
COL10A1, COL11A1, COL11A2, COL1A1, COL1A2, 
COL2A1, COL9A1, COL9A2, COL9A3, COMP, 
CREB3L1, CRTAP, CTSK, CUL7, DDR2, DHCR24, 
DLL3, DLX3, DMP1, DYM, DYNC2H1, EBP, EFNB1, 
EFTUD2, EIF2AK3, ENPP1, ESCO2, EVC, EVC2, 
EXT1, EXT2, FAM20C, FBLN1, FBN1, FBXW4, 
FERMT3, FGF10, FGF23, FGF9, FGFR1, FGFR2, 
FGFR3, FKBP10, FLNA, FLNB, FMN1, FOXC1, 
GALNT3, GDF5, GLI3, GNAS, GORAB, GPC6, GPX4, 
GREM1, HDAC4, HOXA11, HOXD13, HPGD, HSPG2, 
ICK, IFITM5, IFT122, IFT140, IFT172, IFT43, IFT80, 
IFT88, IHH, IKBKG, IL1RN, INPPL1, KAT6B, KIF22, 
KIF7, LBR, LEMD3, LEPRE1, LFNG, LIFR, LMBR1, 
LMNA, LMX1B, LRP4, LRP5, MAFB, MATN3, MESP2, 
MGP, MKS1, MMP13, MMP2, MMP9, MSX2, MYCN, 
NEK1, NIPBL, NKX3-2, NLRP3, NOG, NOTCH2, 
NPR2, NSDHL, OBSL1, OFD1, ORC1, ORC4, ORC6, 
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OSTM1, PAPSS2, PCNT, PEX7, PHEX, PIGV, PITX1, 
PLEKHM1, PLOD2, POLR1C, POR, PPIB, PRKAR1A, 
PTDSS1, PTH1R, PTHLH, PTPN11, PYCR1, RAB23, 
RASGRP2, RECQL4, ROR2, RPGRIP1L, RUNX2, 
SALL1, SALL4, SBDS, SERPINF1, SERPINH1, SH3BP2, 
SH3PXD2B, SHH, SHOX, SLC25A12, SLC26A2, 
SLC34A3, SLC35D1, SLC39A13, SMARCAL1, SOST, 
SOX9, SP7, SULF1, TBCE, TBX15, TBX3, TBX4, TBX5, 
TBXAS1, TCIRG1, TCOF1, TCTN3, TGFB1, THPO, 
TMEM216, TMEM38B, TMEM67, TNFRSF11A, 
TNFRSF11B, TNFSF11, TP63, TRAPPC2, TREM2, 
TRIP11, TRPS1, TRPV4, TTC21B, TWIST1, TWIST2, 
TYROBP, WDR19, WDR34, WDR35, WDR60, WISP3, 
WNT3, WNT5A, WNT7A, ZMPSTE24.
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